ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally.
Solid track record with excellent balance sheet.
Share Price & News
How has ICON's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ICLR's share price has been volatile over the past 3 months.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: ICLR exceeded the US Life Sciences industry which returned -7.6% over the past year.
Return vs Market: ICLR exceeded the US Market which returned -11.9% over the past year.
Price Volatility Vs. Market
How volatile is ICON's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StDo You Like ICON Public Limited Company (NASDAQ:ICLR) At This P/E Ratio?
3 weeks ago | Simply Wall StIs ICON (NASDAQ:ICLR) Using Too Much Debt?
1 month ago | Simply Wall StHere's What Analysts Are Forecasting For ICON Public Limited Company After Its Yearly Results
Is ICON undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ICLR ($135.04) is trading below our estimate of fair value ($150.49)
Significantly Below Fair Value: ICLR is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: ICLR is good value based on its PE Ratio (19.7x) compared to the Life Sciences industry average (29x).
PE vs Market: ICLR is poor value based on its PE Ratio (19.7x) compared to the US market (13x).
Price to Earnings Growth Ratio
PEG Ratio: ICLR is poor value based on its PEG Ratio (2.1x)
Price to Book Ratio
PB vs Industry: ICLR is overvalued based on its PB Ratio (4.5x) compared to the US Life Sciences industry average (4.2x).
How is ICON forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ICLR's forecast earnings growth (9.5% per year) is above the savings rate (1.7%).
Earnings vs Market: ICLR's earnings (9.5% per year) are forecast to grow slower than the US market (12.3% per year).
High Growth Earnings: ICLR's earnings are forecast to grow, but not significantly.
Revenue vs Market: ICLR's revenue (7.1% per year) is forecast to grow slower than the US market (7.3% per year).
High Growth Revenue: ICLR's revenue (7.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ICLR's Return on Equity is forecast to be high in 3 years time (29.5%)
How has ICON performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ICLR has high quality earnings.
Growing Profit Margin: ICLR's current net profit margins (13.1%) are higher than last year (12.4%).
Past Earnings Growth Analysis
Earnings Trend: ICLR's earnings have grown by 12.4% per year over the past 5 years.
Accelerating Growth: ICLR's earnings growth over the past year (14.3%) exceeds its 5-year average (12.4% per year).
Earnings vs Industry: ICLR earnings growth over the past year (14.3%) underperformed the Life Sciences industry 21.5%.
Return on Equity
High ROE: ICLR's Return on Equity (22.7%) is considered high.
How is ICON's financial position?
Financial Position Analysis
Short Term Liabilities: ICLR's short term assets ($1.6B) exceed its short term liabilities ($1.1B).
Long Term Liabilities: ICLR's short term assets ($1.6B) exceed its long term liabilities ($118.7M).
Debt to Equity History and Analysis
Debt Level: ICLR's debt to equity ratio (21.1%) is considered satisfactory.
Reducing Debt: ICLR's debt to equity ratio has increased from 0.02% to 21.1% over the past 5 years.
Debt Coverage: ICLR's debt is well covered by operating cash flow (118%).
Interest Coverage: ICLR's interest payments on its debt are well covered by EBIT (67.5x coverage).
Inventory Level: ICLR has a low level of unsold assets or inventory.
Debt Coverage by Assets: ICLR's debt is covered by short term assets (assets are 4.6x debt).
What is ICON's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ICLR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ICLR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ICLR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ICLR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ICLR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steve Cutler (59yo)
Dr. Steven A. Cutler, also known as Steve, Ph.D., MBA, has been the Chief Executive Officer of ICON Public Limited Company since March 01, 2017, Dr. Cutler is the Chief Operating Officer of ICON at ICON C ...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD7.67M) is about average for companies of similar size in the US market ($USD7.34M).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
|CEO & Director||3yrs||US$7.67m||0.057% $4.1m|
|Chief Financial Officer||8.08yrs||US$2.24m||0.027% $2.0m|
|Vice President of Corporate Finance & Investor Relations||no data||no data||no data|
|Chief Information Officer||no data||no data||no data|
|Chief Administrative Officer||3.67yrs||no data||no data|
|Executive Vice President of Investor Relations & Corporate Development||7.42yrs||no data||no data|
|Director of Corporate Communications||no data||no data||no data|
|Chief Human Resources Officer||3.67yrs||no data||no data|
|Executive Vice President of Program Management||1.17yrs||no data||no data|
|Senior Vice President of Global Clinical Pharmacology||10.92yrs||no data||no data|
Experienced Management: ICLR's management team is considered experienced (3.7 years average tenure).
|CEO & Director||3yrs||US$7.67m||0.057% $4.1m|
|Independent Non-Executive Director||6yrs||US$407.00k||no data|
|Founder & Independent Non-Executive Director||10.17yrs||US$395.00k||1.14% $82.4m|
|Independent Non-Executive Director||2.42yrs||US$287.00k||no data|
|Non-Executive Chairman of the Board||3yrs||US$543.00k||no data|
|Independent Non-Executive Director||7yrs||US$424.00k||no data|
|Lead Independent Director||1.17yrs||US$362.00k||no data|
|Independent Non-Executive Director||2.33yrs||US$296.00k||no data|
|Independent Non-Executive Director||5.92yrs||US$407.00k||no data|
|Independent Non-Executive Director||0.67yr||US$116.00k||no data|
Experienced Board: ICLR's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
ICON Public Limited Company's company bio, employee growth, exchange listings and data sources
- Name: ICON Public Limited Company
- Ticker: ICLR
- Exchange: NasdaqGS
- Founded: 1990
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$7.241b
- Shares outstanding: 53.62m
- Website: https://www.iconplc.com
Number of Employees
- ICON Public Limited Company
- South County Business Park
- Co. Dublin
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IJF||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||May 1998|
|ICLR||NasdaqGS (Nasdaq Global Select)||Yes||Ordinary Shares||US||USD||May 1998|
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company’s clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. Its clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. The company was founded in 1990 and is headquartered in Dublin, Ireland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/29 02:55|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.